Medeiros Marcelo, Diniz Debora, Schwartz Ida Vanessa Doederlein
Departamento de Sociologia, Universidade de Brasília, Brasília, DF, 70673-970.
Cien Saude Colet. 2013 Apr;18(4):1079-88. doi: 10.1590/s1413-81232013000400022.
This paper evaluates the hypothesis that the judicialization of medicine for mucopolysaccharidosis in Brazil is an action promoted by economic elites. Previous studies upholding the thesis of judicialization by elites in the case of other types of medication that are more costly for the Unified Health Service are discussed. An analysis of all 196 processes containing information about judicial processes brought to court between February 2006 and December 2010 that ended by determining that the State should provide such medication free of charge to patients was conducted. There is evidence that attorneys' fees were covered by entities interested in the results of judicialization, such as the distributors or pharmaceutical industries. Patients may also be migrating for diagnosis and treatment to university centers that are a benchmark for medical innovation in the country, as the option for public health services is related to their higher technical and scientific capacity. Therefore, the resort to private lawyers, indicators of social exclusion based on the address of patients and the use of public health services, are not adequate class information to corroborate or refute the thesis of judicialization by the elites.
本文评估了这样一种假设，即巴西黏多糖贮积症药物的司法化是经济精英推动的一项行动。文中讨论了先前支持精英阶层在其他对统一医疗服务成本更高的药物案例中司法化论点的研究。对2006年2月至2010年12月期间提交给法院的所有196个司法程序进行了分析，这些程序包含司法程序信息，最终判定国家应为患者免费提供此类药物。有证据表明，律师费由对司法化结果感兴趣的实体支付，如经销商或制药行业。患者也可能前往作为该国医学创新标杆的大学中心进行诊断和治疗，因为选择公共卫生服务与这些中心更高的技术和科学能力有关。因此，求助于私人律师，这基于患者住址和公共卫生服务使用情况的社会排斥指标，并非足以证实或反驳精英阶层司法化论点的充分类别信息。
